|
- Soleno Therapeutics – Development and commercialization of novel . . .
Soleno is committed to maximizing shareholder value by developing and commercializing innovative therapeutic products with the goal of improving the lives of individuals living with complex, life-threatening rare diseases with unmet medical needs
- Products - Soleno
For commercial and industrial use Trench Drain for residential, commercial and industrial use TripleFlo is the triple-wall pipe offered exclusively by Soleno Rigid pipe with smooth interior and exterior walls for drainage applications Composed of three interconnected layers of HDPE, it is designed to offer an exceptional level of rigidity
- ABOUT US - Soleno USA
With more than 550 employees across 13 industrial sites, the Group SOLENO is one of the largest manufacturers of HDPE pipes and one of the largest plastic recyclers in Eastern Canada
- Soleno Therapeutics Receives Breakthrough Therapy Designation from U. S . . .
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases The company’s lead candidate, DCCR extended-release tablets, a once-daily oral tablet, recently completed its Phase 3 development program in patients with PWS to support a planned NDA submission
- Welcome to Soleno Therapeutics Medical Affairs
Access medical content and resources intended for U S healthcare providers to facilitate the exchange of scientific information and educational resources regarding Soleno medicines and therapeutic areas of interest
- Soleno Therapeutics, Inc. (SLNO) is a Great Momentum Stock: Should You Buy?
Does Soleno Therapeutics, Inc (SLNO) have what it takes to be a top stock pick for momentum investors? Let's find out
- Soleno
Les solutions et produits offerts par Soleno permettent un accès optimal à la forêt et un drainage efficace afin de préserver et prolonger la durée de vie des chemins forestiers
- Soleno jumps as analysts say US nod for rare disease drug transforms . . .
Shares of Soleno Therapeutics jumped 40% in morning trading on Thursday, after the company's drug for a rare metabolic condition became the first such treatment to receive U S regulatory nod
|
|
|